Literature DB >> 26296268

National Analysis of Short-Term Outcomes After Pulmonary Resections on Cardiopulmonary Bypass.

Andreas R de Biasi1, Abu Nasar1, Paul C Lee1, Jeffrey L Port1, Brendon Stiles1, Arash Salemi1, Leonard Girardi1, Nasser K Altorki1, Subroto Paul2.   

Abstract

BACKGROUND: Pulmonary resections using cardiopulmonary bypass (CPB) are infrequently performed. Their short-term outcomes are not well described. We queried the National Inpatient Sample over a 10-year period (2001 to 2011) to more clearly delineate the short-term outcomes of patients undergoing pulmonary resections on CPB.
METHODS: We identified all patients 18 years and older who underwent pulmonary lobectomy (LB) or pneumonectomy (PN) on CPB; lung transplantations were excluded. We then grouped these patients based on the setting in which bypass was used: LB/PN with planned CPB (group 1), LB/PN with concomitant on-pump cardiac procedure (group 2), or LB/PN requiring CPB secondary to injury (group 3). Demographic data and inhospital outcomes were obtained for each patient.
RESULTS: In all, 843 patients underwent LB or PN on CPB during the study period. Lobectomies were the most commonly performed procedure overall. Inhospital mortality for groups 1, 2, and 3 were 22% (n = 58), 16% (n = 61), and 57% (n = 115), respectively. Complications were prevalent across all groups. Routine discharge was achieved by fewer than half of all patients: 48% of group 1 (n = 128); 34% of group 2 (n = 129); and 18% of group 3 (n = 36). Pneumonectomy (odds ratio 2.74, 95% confidence interval: 1.00 to 7.53, p = 0.049) as well as using CPB either as part of a combined cardiac surgery (odds ratio 1.48, 95% confidence interval: 0.39 to 5.59, p = 0.002) or because of injury (odds ratio 6.52, 95% confidence interval: 2.13 to 19.99, p = 0.002) were found to be significant multivariate predictors of short-term mortality.
CONCLUSIONS: Pulmonary resections on CPB carry considerable short-term mortality and morbidity, but some risk can be partially mitigated when bypass is planned preoperatively.
Copyright © 2015 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26296268     DOI: 10.1016/j.athoracsur.2015.05.085

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

1.  Initial extended resection or neoadjuvant therapy for T4 non-small cell lung cancer-What is the evidence?

Authors:  Ilkka Ilonen; David R Jones
Journal:  Shanghai Chest       Date:  2018-10-11

Review 2.  Atrial resection for T4 non-small cell lung cancer with left atrium involvement: a systematic review and meta-analysis of survival.

Authors:  Shadi Hamouri; Nasr Alrabadi; Sebawe Syaj; Hassan Abushukair; Obada Ababneh; Leen Al-Kraimeen; Majd Al-Sous; Erich Hecker
Journal:  Surg Today       Date:  2022-01-09       Impact factor: 2.549

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.